Jirge, 2016 - Google Patents
Poor ovarian reserveJirge, 2016
View HTML- Document ID
- 3298813141867241907
- Author
- Jirge P
- Publication year
- Publication venue
- Journal of human reproductive sciences
External Links
Snippet
Poor ovarian reserve (POR) is an important limiting factor for the success of any treatment modality for infertility. It indicates a reduction in quantity and quality of oocytes in women of reproductive age group. It may be age related as seen in advanced years of reproductive life …
- 230000002611 ovarian 0 title abstract description 106
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jirge | Poor ovarian reserve | |
Vaiarelli et al. | What is new in the management of poor ovarian response in IVF? | |
Broer et al. | The role of anti-Müllerian hormone assessment in assisted reproductive technology outcome | |
Iliodromiti et al. | Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study | |
Swanton et al. | IVF outcome in women with PCOS, PCO and normal ovarian morphology | |
Kumbak et al. | Female obesity and assisted reproductive technologies | |
Hernández-Angeles et al. | Early menopause: A hazard to a woman's health | |
de Ziegler et al. | The value of growth hormone supplements in ART for poor ovarian responders | |
Fábregues et al. | Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down-regulated women of advanced reproductive age | |
Baker | Primary ovarian insufficiency in the adolescent | |
Krishna et al. | Gonadotropin-releasing hormone agonist trigger is a better alternative than human chorionic gonadotropin in PCOS undergoing IVF cycles for an OHSS Free Clinic: A Randomized control trial | |
Chen et al. | Timing of human chorionic gonadotropin (hCG) hormone administration in IVF/ICSI protocols using GnRH agonist or antagonists: a systematic review and meta-analysis | |
Reichman et al. | Consecutive gonadotropin-releasing hormone-antagonist in vitro fertilization cycles: does the elapsed time interval between successive treatments affect outcomes? | |
O'neill et al. | Use of gonadotropin-releasing hormone agonist trigger during in vitro fertilization is associated with similar endocrine profiles and oocyte measures in women with and without polycystic ovary syndrome | |
Seckin et al. | The role of anti-Müllerian hormone in prediction of pregnancy in young and older women with unexplained infertility undergoing intrauterine insemination | |
Jirge et al. | Ovarian stimulation in assisted reproductive technology cycles for varied patient profiles: an indian perspective | |
Marci et al. | In vitro fertilization stimulation protocol for normal responder patients | |
Mendoza-Tesarik et al. | GnRH agonist treatment of luteal phase deficiency in HCG-triggered IVF cycles: a matched case-control study | |
Howell et al. | Preconception evaluation before in vitro fertilization | |
Matorras et al. | Meta‐analysis of the embryo freezing transfer interval | |
Paterson et al. | Improved pregnancy rates with luteinizing hormone supplementation in patients undergoing ovarian stimulation for IVF | |
Setton et al. | Body mass index is not associated with donor oocyte recipient success: an ideal study using a paired analysis of sibling-oocytes | |
Singh et al. | Do increased levels of progesterone and progesterone/estradiol ratio on the day of human chorionic gonadotropin affects pregnancy outcome in long agonist protocol in fresh in vitro fertilization/intracytoplasmic sperm injection cycles? | |
Papaleo et al. | Natural cycle as first approach in aged patients with elevated follicle-stimulating hormone undergoing intracytoplasmic sperm injection: a pilot study | |
Popovic-Todorovic et al. | Added value today of hormonal measurements in ovarian stimulation in gonadotropin-releasing hormone antagonist treatment cycle |